Preclinical Research Services

The increasing prevalence of cancers makes preclinical evaluations of seprase (FAP) -targeted drugs a critical factor in ensuring the safety, efficacy, and pharmacological properties of these therapeutics. Alfa Cytology stands at the forefront of providing preclinical research services for seprase (FAP)-targeted drug development, offering a comprehensive suite of solutions through state-of-the-art technologies.

Introduction to Preclinical Research

Seprase (FAP) is an attractive target in cancer therapy and diagnostics. Accordingly, many new FAP-tracers have been developed for targeted radionuclide imaging and, more recently, targeted radionuclide therapy (TRT). Preclinical studies are crucial for screening potential seprase (FAP)-targeted radiopharmaceuticals and for gaining a deeper understanding of the key factors involved in the effects of targeted seprase (FAP) drugs.

Fig. 1 The clinical [18F]AlF-FAP-NUR PET/CT images, H&E results and FAP-IHC staining of primary lesions in patients. (Liu, S., et al. 2024)

Our Services

At Alfa Cytology, we combine various research models and methods to comprehensively evaluate and test the safety, efficacy, and pharmacokinetic properties of seprase (FAP)-targeted drugs. This approach allows us to pave the way for the advancement of these drugs into subsequent trial phases.

Our Preclinical Research Services

Innovations in methodologies have driven rapid growth in the area of preclinical research services, making them essential for the development of seprase (FAP)-targeted therapeutics. Alfa Cytology provides preclinical research services to support the development of seprase (FAP)-targeted drugs. Contact us for more information and pricing details on our services.

For research use only.